People looking for weight-loss medicines often meet a confusing mix of brand names, diabetes medicines and old myths about what is or is not available. A good overview starts with the approved indications and then looks at the practical differences.
Which medicines are relevant in Sweden in 2026?
The strongest current focus is on GLP-1-based and dual-agonist obesity medicines with meaningful clinical data for appetite regulation and weight loss.
How Wegovy and Mounjaro differ
They differ in active substance, dose escalation, average study outcomes, side-effect profile and how individual patients respond over time.
What is not approved for obesity?
Not every medicine discussed online is approved specifically for obesity, which is why off-label assumptions should be treated carefully.
How access and pricing work
Prescription access still depends on medical assessment, while the final practical choice is often shaped by cost, supply and follow-up model.